Intercept Pharmaceuticals is one step closer to getting FDA approval for the first-ever NASH drug
February 19, 2019 at 12:15 PM EST
Intercept Pharmaceuticals Inc. announced Tuesday that a potential therapy for the fatty liver disease known as NASH had achieved its primary goal in a Phase 3 trial, a week after Gilead Sciences Inc. announced a competing trial had failed.
